# CATALYST BIOSCIENCES

Corporate Overview 12 January 2022



## **Forward looking statements**

Certain information contained in this presentation and statements made orally during this presentation include forward-looking statements that involve substantial risks and uncertainties. All statements included in this presentation, other than statements of historical facts, are forward-looking statements. This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include, without limitation, our plans for CB 4332 and the rest of our complement programs, our plans to continue to support Biogen in the development of CB 2782-PEG, the statement that complement has broad potential, can be combined with conventional therapies and will open opportunities in multiple disease settings, as well as statements about the benefits of our protease engineering platform.

Actual results or events could differ materially from the plans, intentions, expectations, and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially, including, but not limited to, the risk that clinical trials and preclinical studies may be delayed as a result of COVID-19, competitive products, and other factors, that Biogen could terminate our agreement for the development of CB 2782-PEG, that our complement degraders are not yet in human clinical trials and will require additional manufacturing validation and preclinical testing before entering human clinical trials, that we may need to raise additional capital, and other risks described in the "Risk Factors" section of our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 4, 2021, the Quarterly Report on Form 10-Q filed with the SEC on November 12, 2021, and in other filings filed from time to time with the SEC. We do not assume any obligation to update any forward-looking statements, except as required by law.



# Modulating Biological Systems with Nature's Regulatory Proteins

Proteases are nature's key regulatory proteins

- ( Innovative engineered molecules to degrade or activate therapeutic targets
- Applicable across multiple disease areas

We harness the regulatory power of proteases







#### Complement

SQ CB 4332 Enhanced CFI

IVT CB 2782-PEG C3 degrader for Dry AMD

C3b/C4b degraders

C3a/C5a degraders

**Partnering opportunities** 

#### Hemostasis

#### SQ Marzeptacog alfa (FVIIa) "MarzAA"

- Hemophilia A or B with inhibitors
- FVIID/Glanzmann/Hemlibra

SQ Dalcinonacog alfa (FIX) "DalcA"

R

• Hemophilia B







#### FIX) "DalcA" CB 2679d-GT


• Hemophilia B FIX Gene Therapy

**P1** 

### **Catalyst's protease platform in complement** Validated across three programs


### CB 2782-PEG Biogen

Best-in-class profile for dry AMD Extended pharmacodynamics



### **CB 4332 PK extended CFI**

Restoring balance to complement where CFI activity is insufficient





Engineered CFI entering the clinic in 2022



 $\langle \rangle$ 


### **Engineered proteases**

Protease platforms tailored to improve C3b & C4b regulation



C3b/C4b degrader platform delivering candidates in 2022


## Unique targeted approach to complement regulation





Catalyst protease and protein degrader discovery platform Distinct expertise enables design of optimal therapeutic candidates

#### **Protease Discovery Platform**





# Therapeutic advantages of protein degraders



Controlled target engagement



Fast elimination of difficult targets



Tunable for high potency & affinity




Modulate instead of inactivating




Can be combined with conventional therapies

### Nature's way to regulate complement A platform based on the natural braking mechanisms of complement




- Solution Rebalances complement using the natural brakes (CFI)
- Multiple diseases driven by C3b/C4b deposition & immune activation
- S Differentiated mechanisms to regulate at or around C3 & C5
- Safely regulate complement without broad immunosuppression
- Uses the natural regulatory protein to modulate the complement system






### Nature's way to regulate complement A platform based on the natural braking mechanisms of complement





### Our protease platforms are tailored to specific indications **Tuning functionality to restore complement homeostasis & immunoregulation**

**Nephrology** 





Specific inhibition of complement components at different sites of the complement cascade allows a personalized approach to treating complement disorders






# CB 4332 Half-Life Extended Complement Factor I to rebalance the complement system





### CB 4332: Extended half-life Complement Factor I

### **Development candidate to restore regulation**



#### + Engineered for an extended half-life

+ Potential for once weekly SQ therapy

#### + In vitro & ex vivo activity comparable to native CFI


- + Classical & alternative pathway regulation
- + High yield production process
- + Safe GLP toxicology with a high dosing window
- + Entering the clinic in 2022







### **Rationale & unmet need**

- + Rebalance the complement system in patients with insufficient complement regulation
- + No specific therapies exist to correct complement dysregulation using natural proteases
- + Potentially targets a population with no treatment or who respond poorly to current treatments<sup>1,2</sup>








\*Patient population estimate does not include age-related macular degeneration US population with rare CFI variants AMD: Age-Related Macular Degeneration, aHUS: atypical Hemolytic Uremic Syndrome, C3G: C3 Glomerulonephropathy, SLE: Systemic Lupus Erythematosus, LN: Lupus Nephritis, AIHA: Autoimmune Hemolytic Anemia, ANCA: ANCA-associated Vasculitis, ITP: Immune Thrombocytopenia, HAE: Hereditary Angioedema, APS: Antiphospholipid Antibody Syndrome

### CB 4332 may target diseases of excessive C3b and C4b deposition Deposition of C4b & C3b in AIHA lead to hemolysis & cellular destruction






CB 4332 protects against C3b driven hemolysis


Degradation of C3b to C3d leads to cellular survival

CFI is the natural inactivator & degrader of C3b to C3d

# C3b & C4b Degraders Broad applications in complement-mediated disorders



## Improved catalytic power & specificity for CFI variants **ProTUNE™** platform has been used to generate specific C3b/C4b degraders




© Catalyst Biosciences



### **Precision CFI Therapeutics**

- Tunable potency to control dysregulated complement
- **Tunable specificity** 
  - toward C3b & C4b to restore balance to the complement cascade
- **Preserves innate** immune response by sparing cascade leading to MAC formation

### Using **ProTUNE<sup>TM</sup>** Platform to tune C3b & C4b cleaving capabilities






### **Reduction of Hemolysis**


### **Cofactor independent CFI may target patient subpopulations ProTUNE™** platform has generated degraders that work without cofactors


#### **Cofactor Dependent**

**Alternative Pathway Hemolysis** 



#### **Cofactor Independent**





of addressable patients

cofactors are insufficient




- Cofactor independent molecules broaden the scope
- Independently regulates C3b/C4b levels when

## C3b & C4b degraders significantly reduce inflammation in vivo


Rat sepsis model of complement activation

Reduction of IFN $\gamma$ , TNF $\alpha$ , and RANTES that are chemokines involved in kidney damage and proteinuria in IgA nephropathy patients

Concomitant reduction of inflammatory markers and complement C3 cleavage



# Inflammatory markers in IgA nephropathy








### Example: C3b/C4b degraders for IgA nephropathy patients Disease in which both lectin & alternative pathways drive pathogenesis


### High unmet need – current treatments only address symptoms

- + Most common form of glomerulopathy with accumulation & deposition of IgA immune complexes deteriorating renal function
- + ~10% patients with rapidly progressive glomerulonephritis
- + ~40% of IgAN patients develop end stage renal disease over
  20 years & need dialysis/renal transplant in order to survive
- + C3b/C4b degraders will modulate the alternative & lectin pathways to address complement dysregulation with low off-target effects
- + Significant burden on healthcare resources with an estimated cost of **\$49.2 billion** in 2020 in the US





## Example: C3b/C4b degraders for IgA nephropathy Dual targeting of alternative <u>&</u> lectin pathways





### Differentiation

 + Dual targeting mode of action: lectin & alternative pathways

#### **Rationale for IgA nephropathy**


+ Both lectin & alternative pathways are involved in IgA nephropathy & correlate with severe clinical manifestation <sup>1, 2, 3</sup>

#### **Clinically validated targets**


Inhibition of only MASP2 or Factor B
 may be insufficient to reduce
 proteinuria in IgA nephropathy patients

# C3a & C5a Degraders For inflammatory disorders

© Catalyst Biosciences



### **Dialing catalytic power & specificity to restore immunoregulation** Using the ImmunoTUNE<sup>™</sup> engineering platform to tune C3a/C5a degraders





#### **Precision Therapeutics**

- Modified C3a/C5a
  - Desired Functionality

### control dysregulated complement

Tunable potency to


**Tunable specificity**  $\langle \rangle$ toward C3a & C5a to restore balance to the complement cascade

#### **Preserves host** $\langle \rangle$ immune response

23

C3a/C5a degraders: Efficacy in acute LPS-induced ARDS model Improves respiratory function & reduces cell infiltrates in an acute setting


**Respiratory functions & cell infiltration at 24 h** 




CB 6000 outperforms anti-C5 antibody<sup>1</sup> in reducing inflammatory cell infiltration CB 6000 compares well on respiratory functions with anti-C5 antibody



#### Mouse LPS model of lung inflammation



### Example: C3a/C5a degraders: Potential for ANCA Vasculitis patients Autoimmune disease where anaphylatoxins play a role in the pathogenesis




### High unmet need – current treatments only addressing symptoms

- + Autoimmune disorder characterized by inflammation & destruction of small blood vessels
- Clinical signs vary & affect several organs with frequent involvement of upper respiratory track & kidneys
- Severe pain due to neuropathy, pulmonary hemorrhages, failure of kidneys +
- **10-15%** of patients die within the 1<sup>st</sup> year of treatment with +conventional therapies (immunosuppressant & steroids)
- The only treatments available are to manage the symptoms





### Example: C3a/C5a degraders: Potential for ANCA Vasculitis patients **Dual targeting of both C3a** <u>&</u> C5a with one protease medicine



<sup>1</sup>S. Moiseev et al. British Society for Immunology, Clinical and Experimental Immunology (2020); <sup>2</sup>Gou et al. Kidney International (2012). © Catalyst Biosciences



### **Rationale for ANCA Vasculitis**

+ Both C3a & C5a levels are elevated in active ANCA associated vascuiltis patients <sup>1, 2</sup>

### Differentiation


- + Degrade activation products of C3 (C3a) & C5 (C5a) that are inflammatory mediators
- + Unlike Avacopan, may provide beneficial function via blocking the C5L2 pathway, an alternative receptor for C5a

### **Clinically validated targets**

+ Inhibition of C5a or C5aR alone may be **insufficient** to increase remission rates in ANCA associated vasculitis patients


# CB 2782-PEG Novel engineered C3 degrader

Partnered with Biogen.



© Catalyst Biosciences

## Complement inhibition is a validated approach in dry AMD






#### **Complement inhibition shows promising reduction in GA growth**

Category	Route	Dose level	Frequency	Inhibition GA growth
CFI gene therapy	Subretinal	2E <sup>11</sup> vg	Once	Unknown
PEGylated amino acid cyclic peptide	Intravitreal	15 mg	1-2 months	20-30%
Antibody anti-C3	Intravitreal	15 mg	1-2 months	Unknown
pegylated RNA aptamer	Intravitreal	2 mg	1-2 months	20-30%
PEGylated anti-C3 protease	Intravitreal	Low undisclosed	<b>2-3 months</b> Model of NHP data	Unknown

### CB 2782-PEG: Best-in-class C3 degrader for dry AMD The protease advantage demonstrated *in vivo*

CB 2782-PEG degrades C3 levels in the eye for at least 28 days in a non-human primate model





### **Catalytic advantage of proteases**


- One therapeutic molecule neutralizes 1000s
- + Fast & potent response
  - Extended pharmacodynamic effect
  - Can activate or degrade therapeutic targets
- + Engineered novel protein degraders "sweep away" difficult to drug targets

### Catalyst Biosciences protease platform has broad potential Building on nature's way of regulating key processes in health & disease

- Catalyst develops enhanced natural core proteases & protease degraders targeting complement regulation
- - Catalyst has designed optimized, next-generation complement degrader candidates
- - Complement dysregulation serves as **driver** for many diseases with **unmet needs**
- Catalyst has **protease programs** designed to take advantage of nature's natural complement regulators that **restore complement homeostasis** & potentially treat **other** complement-mediated disorders
- Application of Catalyst's protease & protein degrader technology could unlock treatments in immunology, nephrology, hematology, ocular diseases, and beyond



### **Overview of complement portfolio** Multiple value generating events in 2022 & 2023





#### 2023

**Clinical Development of Initial Indication** 

Clinical **Development** 

Preclinical

# THANK YOU

www.CatalystBiosciences.com

